10q10k10q10k.net
Charles River Laboratories

Charles River LaboratoriesCRLEarnings & Financial Report

NYSE · Health Care · Life Sciences Tools & Services

Charles River Laboratories International, Inc. is an American pharmaceutical and biotechnology contract research organisation (CRO) headquartered in Wilmington, Massachusetts, United States. Founded in 1947, the company provides preclinical and clinical laboratory services for the development of new drugs, vaccines, and medical devices.

CRL Q4 2025 Key Financial Metrics

売上高

$994.2M

粗利益

N/A

営業利益

$-283.4M

純利益

$-276.6M

粗利益率

N/A

営業利益率

-28.5%

純利益率

-27.8%

前年比成長

-0.8%

EPS

$-5.57

資金フロー

Charles River Laboratories Q4 2025 Financial Summary

Charles River Laboratories reported revenue of $994.2M for Q4 2025, with a net profit of $-276.6M (-27.8% margin). Cost of goods sold was N/A, operating expenses totaled N/A.

Key Financial Metrics

Total Revenue$994.2M
Net Profit$-276.6M
Gross MarginN/A
Operating Margin-28.5%
Report PeriodQ4 2025

Charles River Laboratories Annual Revenue by Year

Charles River Laboratories annual revenue history includes year-by-year totals (for example, 2025 revenue was $4.0B).

YearAnnual Revenue
2025$4.0B
2024$4.0B
2023$4.1B
2022$4.0B

損益計算書

Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025
売上高$1.01B$1.03B$1.01B$1.00B$984.2M$1.03B$1.00B$994.2M
前年比成長N/A-0.3%-4.7%N/A-2.7%0.6%-0.5%-0.8%

貸借対照表

Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025
総資産$8.15B$7.95B$8.00B$7.53B$7.58B$7.56B$7.51B$7.14B
総負債$4.45B$4.18B$4.18B$4.02B$4.34B$4.16B$4.06B$3.92B
株主資本$3.64B$3.72B$3.78B$3.46B$3.19B$3.35B$3.41B$3.16B

キャッシュフロー

Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025
営業CF$129.9M$193.5M$251.8M$159.4M$171.7M$204.6M$213.8M$147.5M